Lv11
38 积分 2025-11-19 加入
Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039
39分钟前
待确认
Reaching new heights? Maximum subcutaneous injection volumes from a technical and clinical development strategy perspective
14天前
已完结
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug–Drug Interactions for Firsocostat, a Liver-Targeted Inhibitor of Acetyl-CoA Carboxylase
28天前
已完结
64499 Design of Lunsayil, an Adaptive Phase 2b/Phase 3 Clinical trial of Spesolimab in Patients With Moderate-to-Severe Hidradenitis Suppurativa
1个月前
已关闭
A 2024 Update on US FDA Implementation of Partial Area Under the Curve Into Bioavailability and Bioequivalence Assessments
2个月前
已完结
Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial
2个月前
已完结
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial
3个月前
已完结
The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model
4个月前
已完结
Research Landscape of Physiologically Based Pharmacokinetic Model Utilization in Different Fields: A Bibliometric Analysis (1999–2023)
4个月前
已完结
Positive implications of PBPK platform qualification for predicting drug–drug interactions: Taking on cracks only to see bigger gaps!
4个月前
已完结
皖公网安备34019202002308
